drugset / Trial / NCT05234905
H101 Combined With Camrelizumab for Recurrent Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
There is no standard treatment for recurrent cervical cancer that progresses or persists after first-line treatment. The objective response rate of anti-PD-1 antibody treatment is about 15%. The purpose of this study was to evaluate whether the regimen could improve the objective response rate by intratumoral injection of oncolytic virus(recombinant human adenovirus type 5 injection, H101) combined with anti-PD-1 antibody(camrelizumab).
Timeline
- Start
- 2022-03
- Primary completion
- 2023-06
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | H101 | Other / unclassified | 1 vg | Other |
| Subject | H101 | Other / unclassified | 1.5 vg | Other |
| Subject | H101 | Other / unclassified | 2 vg | Other |
| Subject | H101 | Other / unclassified | 3 vg | Other |
| Subject | H101 | Other / unclassified | 4.5 vg | Other |